Zur Rose Group, one of the leading pure play online pharmacies in Europe, has launched its initial public offering. The company wants to use the funds raised primarily to accelerate its growth strategy and to further expand its position as pure play ecommerce pharmacy in Europe.
With the planned listing on Switzerland’s principal stock exchange SIX Swiss Exchange, Zur Rose hopes to raise its capital with 200 million Swiss francs (184 million euros). The first of trading on the Swiss stock exchange is expected to be on or around July 6.
Zur Rose’s plans in Europe
With the funds raised from the IPO, Zur Rose wants to expand its market leadership in Germany. It wants to do this partly by acquiring other companies, both in Germany and in other selected European markets. Zur Rose also wants to develop and invest in data-based solutions and monetize on the Big Data potential.
About Zur Rose
In May 1993, Zur Rose opened its first pharmacy in Steckborn, Switzerland. Later that year it started with supplying doctors with pharmaceutical goods. In 2001, the mail-order pharmacy started with sending medications to patients and in 2012, the company acquired DocMorris, the largest online and mail-order pharmacy of Europe. Currently, the Swiss-based Zur Rose Group operates under the Zur Rose and DocMorris brands.